New Delhi: The Drugs Controller General of India (DCGI) has given permission to Serum Institute of India, a Pune-based vaccine maker, to resume the Phase 2 and Phase 3 clinical ...
Even if a coronavirus vaccine is developed successfully by early next year, there won’t be enough to administer all global citizens till the end of 2024, Serum Institute of India’s ...
Pune: Serum Institute of India’s (SII) phase 2 trial of Oxford's COVID-19 vaccine candidate is set to commence on Tuesday. The determination of safety and immunogenicity of “Covishield” on healthy ...
Pune: Serum Institute of India (SII), on Sunday, issued a clarification that the current claims over commercialising COVISHIELD's availability in 73 days, in the media is completely false and conjectural. ...
New Delhi: Covaxin, the indigenously developed COVID-19 vaccine, has been found to be safe, according to preliminary results of Phase-I clinical trials. Covaxin is developed by Hyderabad-based Bharat Biotech in ...
Mumbai: Serum Institute of India (SII) will make the COVID-19 vaccine available for $3 per dose to low and middle-income countries (LMIC) including India. The world’s largest vaccine manufacturer by ...
India’s Serum Institute and Novavax Inc whose COVID-19 vaccine candidate showed promising results in the initial clinical trials have signed an exclusive supply and license agreement for the production of ...
New Delhi: There is a recommendation to grant permission to the Serum Institute of India (SII) to conduct the second and third phases of human clinical trials of the Oxford ...
Pharmaceutical giant AstraZeneca has promised not to profit from its COVID-19 vaccine, developed in partnership with Oxford University, during the pandemic as the company reported it was on track with ...
Bhubaneswar: Chief Minister Naveen Patnaik on Wednesday spoke to Serum Institute of India CEO Adar Poonawalla over a video call and discussed the progress of COVID vaccine. Naveen expressed happiness ...
Copyright © 2024 Frontier Media
